NYSE:ANRO Alto Neuroscience (ANRO) Stock Price, News & Analysis $25.02 -2.10 (-7.75%) As of 02:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Alto Neuroscience Stock (NYSE:ANRO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Alto Neuroscience alerts:Sign Up Key Stats Today's Range$24.93▼$27.1250-Day Range$21.70▼$35.7552-Week Range$12.51▼$37.48Volume255,227 shsAverage Volume439,209 shsMarket Capitalization$1.00 billionP/E RatioN/ADividend YieldN/APrice Target$37.88Consensus RatingModerate Buy Company Overview Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies. Its drug candidates remain under clinical investigation and are not approved treatments. Founded in 2019 by neuroscientist Amit Etkin, Alto Neuroscience is based in the United States. Etkin has served as the company’s chief executive officer. The company’s research and clinical development focus is on advancing its precision-medicine approach in psychiatry.AI Generated. May Contain Errors. Read More Alto Neuroscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreANRO MarketRank™: 2.078361177405 of 5 starsAlto Neuroscience scored higher than 42% of companies evaluated by MarketBeat, and ranked 650th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingAlto Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAlto Neuroscience has a consensus price target of $37.88, representing about 48.6% upside from its current price of $25.49.Amount of Analyst CoverageAlto Neuroscience has only been the subject of 4 research reports in the past 90 days.Read more about Alto Neuroscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Alto Neuroscience are expected to decrease in the coming year, from ($2.50) to ($2.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alto Neuroscience is -10.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alto Neuroscience is -10.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlto Neuroscience has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.32% of the float of Alto Neuroscience has been sold short.Short Interest Ratio / Days to CoverAlto Neuroscience has a short interest ratio ("days to cover") of 10.51, which indicates bearish sentiment.Change versus previous monthShort interest in Alto Neuroscience has recently increased by 9.19%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlto Neuroscience does not currently pay a dividend.Dividend GrowthAlto Neuroscience does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.74 News SentimentAlto Neuroscience has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Alto Neuroscience this week, compared to 3 articles on an average week. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alto Neuroscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,566,987.00 in company stock.Percentage Held by Insiders11.25% of the stock of Alto Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsAlto Neuroscience has minimal institutional ownership at this time.Read more about Alto Neuroscience's insider trading history. Receive ANRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alto Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANRO Stock News HeadlinesAlto Neuroscience, Inc. (NYSE:ANRO) Stock Has Average Price Target of $37.88November 16 at 2:32 AM | americanbankingnews.comWhat is HC Wainwright's Estimate for ANRO FY2026 Earnings?November 16 at 1:43 AM | americanbankingnews.comEarn $4,500 a month? Your income may count for moreEarn $4,500 or more a month? Pennie lets you explore personal loan options that consider your income, not just your credit score. Options include personal loans up to $250,000 and APRs starting at 5.99%. Checking your rate is free, and the soft credit check won't affect your score. Pennie is a loan marketplace, not a lender. Offers come from third-party partners and are not guaranteed.November 17 at 1:00 AM | Pennie Financial (Ad)Alto Neuroscience (NYSE:ANRO) Earns "Buy" Rating from BTIG ResearchNovember 13, 2026 | americanbankingnews.comAlto Neuroscience faces pivotal 2027 as Jefferies flags three clinical catalystsNovember 11, 2026 | finance.yahoo.comAlto Neuroscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10, 2026 | marketscreener.comMAlto Neuroscience (ANRO) Q3 2026: Burn Rate Beat Funds a Busy 2027November 10, 2026 | 247wallst.comAlto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business HighlightsNovember 10, 2026 | marketscreener.comMSee More Headlines ANRO Stock Analysis - Frequently Asked Questions How have ANRO shares performed this year? Alto Neuroscience's stock was trading at $17.82 at the beginning of the year. Since then, ANRO shares have increased by 43.0% and is now trading at $25.4850. How were Alto Neuroscience's earnings last quarter? Alto Neuroscience, Inc. (NYSE:ANRO) issued its earnings results on Tuesday, November, 10th. The company reported ($0.54) EPS for the quarter, topping analysts' consensus estimates of ($0.67) by $0.13. When did Alto Neuroscience IPO? Alto Neuroscience (ANRO) raised $121 million in an initial public offering on Friday, February 2nd 2024. The company issued 8,040,000 shares at a price of $14.00-$16.00 per share. Who are Alto Neuroscience's major shareholders? Top institutional shareholders of Alto Neuroscience include Bellevue Group AG (2.90%), State Street Corp (2.41%), Marshall Wace LLP (2.14%) and Goldman Sachs Group Inc. (1.01%). Insiders that own company stock include Wave Global Lp Alpha, Adam Savitz and Nicholas Conrad Smith. View institutional ownership trends. How do I buy shares of Alto Neuroscience? Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alto Neuroscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alto Neuroscience investors own include Advanced Micro Devices (AMD), Alphabet (GOOG), PayPal (PYPL), NVIDIA (NVDA), Airship AI (AISP), Dell Technologies (DELL) and Arcellx (ACLX). Company Calendar Last Earnings11/10/2026Today11/17/2026Jefferies Global Healthcare Conference11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ANRO's financial health is in the Green zone, according to TradeSmith. ANRO has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:ANRO Previous SymbolNYSE:ANRO CIK1999480 Webwww.altoneuroscience.com Phone(773) 255-5012FaxN/AEmployees68Year Founded2019Price Target and Rating Average Price Target for Alto Neuroscience$37.88 High Price Target$60.00 Low Price Target$26.00 Potential Upside/Downside+50.2%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.24 million Net MarginsN/A Pretax MarginN/A Return on Equity-41.82% Return on Assets-36.56% Debt Debt-to-Equity Ratio0.04 Current Ratio18.12 Quick Ratio14.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.39 per share Price / Book3.41Miscellaneous Outstanding Shares40,110,000Free Float35,599,000Market Cap$1.01 billion OptionableOptionable Beta1.42 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:ANRO) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.